Suppr超能文献

NF-κB和Bax/Bcl-2/Caspase-3信号通路在沙库巴曲缬沙坦(恩格列净)对高脂饮食/链脲佐菌素诱导的糖尿病肾病保护作用中的作用

The Role of NF-κB and Bax/Bcl-2/Caspase-3 Signaling Pathways in the Protective Effects of Sacubitril/Valsartan (Entresto) against HFD/STZ-Induced Diabetic Kidney Disease.

作者信息

Mohany Mohamed, Ahmed Mohammed M, Al-Rejaie Salim S

机构信息

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, P.O. Box 55760, Riyadh 1145, Saudi Arabia.

出版信息

Biomedicines. 2022 Nov 9;10(11):2863. doi: 10.3390/biomedicines10112863.

Abstract

LCZ696 (valsartan/sacubitril) has the potential to slow the progression of diabetic kidney disease (DKD) according to previous reports. However, the renoprotective mechanism underlying LCZ696 remains unknown. This study aimed to investigate the therapeutic potential and underlying mechanism of LCZ696 in DKD in a type 2 diabetic (T2D) rat model. This model was established in this experiment by feeding a high-fat diet (HFD) for six weeks with a single dose of streptozotocin (STZ, 30 mg/kg body weight). Valsartan or LCZ696 was orally administered to T2D animals for eight weeks. HFD/STZ rats showed hyperglycemia, impaired insulin secretion, significant increases in urea, creatinine, cytokines, nuclear factor kappa B (NF-κB), oxidative stress, caspase-3 activity, glomerular and tubular damage, glomerulsclerosis, Bax and caspese-3 expressions along with a significant decline in IL-10, antioxidant markers, and Bcl-2 expression. The administration of LCZ696 to diabetic rats reduced the serum concentrations of glucose, urea, and creatinine. In addition, ELISA results demonstrated that diabetic rats treated with LCZ696 exhibited a reduction in inflammatory (IL-1β, TNF-α, IL-6) and an increase in anti-inflammatory (IL-10) cytokine levels. In addition, a notable decrease in NF-κB and caspase-3 activity was observed. At the level of renal tissue homogenate, diabetic animals treated with LCZ696 demonstrated clear restorations in GSH content and other antioxidant enzyme levels, in addition to a significant decrease in TBARS levels. In addition, LCZ696 inhibited the expression of the Bax and cleaved caspase-3 proteins and enhanced the expression of the Bcl-2 protein. Improvements in histopathological changes in kidney tissues confirmed and significantly supported these biochemical findings. In summary, LCZ696 alleviated DKD with possible mechanisms including inhibition of inflammation and apoptosis.

摘要

根据先前的报道,LCZ696(缬沙坦/沙库巴曲)有可能减缓糖尿病肾病(DKD)的进展。然而,LCZ696的肾脏保护机制尚不清楚。本研究旨在探讨LCZ696在2型糖尿病(T2D)大鼠模型中对DKD的治疗潜力及其潜在机制。本实验通过给大鼠喂食六周高脂饮食(HFD)并单次注射链脲佐菌素(STZ,30mg/kg体重)建立该模型。将缬沙坦或LCZ696口服给予T2D动物八周。HFD/STZ大鼠表现出高血糖、胰岛素分泌受损、尿素、肌酐、细胞因子、核因子κB(NF-κB)、氧化应激、半胱天冬酶-3活性显著增加,肾小球和肾小管损伤、肾小球硬化、Bax和半胱天冬酶-3表达增加,同时白细胞介素-10、抗氧化标志物和Bcl-2表达显著下降。给糖尿病大鼠施用LCZ696可降低血清葡萄糖、尿素和肌酐浓度。此外,酶联免疫吸附测定(ELISA)结果表明,用LCZ696治疗的糖尿病大鼠炎症细胞因子(白细胞介素-1β、肿瘤坏死因子-α、白细胞介素-6)水平降低,抗炎细胞因子(白细胞介素-10)水平升高。此外,观察到NF-κB和半胱天冬酶-3活性显著降低。在肾组织匀浆水平,用LCZ696治疗的糖尿病动物除丙二醛(TBARS)水平显著降低外,谷胱甘肽(GSH)含量和其他抗氧化酶水平也有明显恢复。此外,LCZ696抑制Bax和裂解的半胱天冬酶-3蛋白的表达,并增强Bcl-2蛋白的表达。肾脏组织病理变化的改善证实并显著支持了这些生化结果。总之,LCZ696减轻了DKD,其可能的机制包括抑制炎症和细胞凋亡。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4757/9717728/2c77851eb593/biomedicines-10-02863-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验